Recurrent Pericarditis: When Colchicine Keeps Failing on Tolerability, Not Efficacy
A single patient, two failed trials into a drug everyone agrees should work. The disagreement isn't about whether colchicine prevents recurrence — it's about whether tolerability failure and treatment failure are the same thing, and what a third attempt should cost him if they're not.
M.T., a 39-year-old man who has run an overnight bakery out of a converted garage for the past six years, arrives at clinic three weeks into his third bout of sharp, positional chest pain — the kind that eases when he leans forward over the mixing bowls and worsens the moment he lies down to sleep before his 2 a.m. shift. He has mild gastroesophageal reflux, managed occasionally with over-the-counter antacids, but no other chronic medical problems. His first episode of acute pericarditis came fourteen months ago, presumed viral, and resolved on high-dose ibuprofen after colchicine caused diarrhea severe enough that he stopped it within ten days. A recurrence eight months ago followed the same pattern: colchicine restarted at the same dose, stopped outright again within two weeks when the diarrhea returned, and a two-week prednisone taper layered on when the NSAID alone wasn't controlling his symptoms. Both episodes eventually settled without recurrence for months at a time.
This time, his ECG again shows diffuse ST-elevation with PR-segment depression, a pericardial friction rub is audible at the left sternal border, his CRP is markedly elevated, and a bedside echo shows a small, hemodynamically insignificant effusion. He has restarted ibuprofen 800 mg three times daily on his own, with some relief, but the pain hasn't cleared. He has no history of renal or hepatic disease, and his baseline labs are otherwise unremarkable. What he wants to know, more than anything, is whether there's a way to make colchicine work for him this time — his shifts start before dawn, and two prior rounds of unpredictable diarrhea have already cost him mornings he couldn't afford to lose.
In clinic, three weeks into recurrence two
Retry colchicine — at the lower end of the weight-based regimen, 0.5 mg once daily instead of twice, taken with food. The recurrence-reduction evidence behind this drug is about as solid as anything we have in pericarditis: CORP, CORP-2, and ICAP all show roughly half the recurrence risk with colchicine added, and the European Society of Cardiology's guideline recommends it from the first episode regardless of how many times someone's already had this. Two discontinuations for diarrhea aren't the same as two failures of the drug itself — plenty of patients who can't tolerate the standard dose do fine on a steadier, lower one, taken alongside the ibuprofen he's already back on.
I'd feel differently if this were a drug with modest benefit and a real safety signal. Colchicine's downside here has been entirely gastrointestinal and self-limited both times he's stopped it — nothing about his prior episodes argues against trying again, just against trying the same dose the same way.
I agree with retrying it, but I want to be honest about what we actually know. The lower, tolerability-driven dose he'd be on has real trial support only for impaired kidney clearance — using it here because his gut couldn't handle the standard dose is a reasonable extrapolation, not an established protocol. What I won't do is default to a prednisone taper as the fallback. The recurrence data linking steroid use to higher relapse rates is observational, not randomized, but it's consistent across every cohort that's looked at it, and neither of his two prior colchicine trials was a genuine dose-optimization attempt — both were abrupt stops, not tapers. That's a real difference, and it matters before we call colchicine finished for him.
None of that makes the reduced dose risk-free for him specifically — if the diarrhea returns at 0.5 mg once daily, we're out of dose to cut, and pretending otherwise going in would be dishonest with him.
Two stops for diarrhea, in a man whose whole workday starts before sunrise, isn't a footnote — it's cost him mornings twice already, and I don't think a third attempt should be presented to him as low-risk when the specific modification we're proposing has never been tested for exactly this reason. I'll support trying it again, but not the way it went the last two times: he gets a call from this office in one week, not at the usual follow-up interval, so if it's failing again we catch it in days instead of finding out after he's already quietly stopped taking it on his own. And if it fails a third time, I think we've learned what we need to learn — a short, monitored prednisone taper is a reasonable next step then, not a last resort to be avoided at all costs.
Agreed: colchicine restarted at 0.5 mg once daily with food, ibuprofen continued at the current dose, and a phone check-in scheduled for one week rather than the standard follow-up interval.
Not agreed, and left as an open branch rather than a shared plan:
The lower dose continues for the standard course, and the question of what caused two prior failures at a higher dose goes unanswered but no longer matters practically.
The cardiologist and pharmacologist favor a further-adjusted colchicine trial before considering steroids; the primary care physician believes a third failure should move straight to a monitored prednisone taper instead.
All three left agreeing on the plan for the next week, and disagreeing about what a third failure should mean — a disagreement that won't need resolving unless the phone call brings bad news.